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Organ distribution of European bat lyssavirus type 2
viral RNA in its reservoir host, Myotis daubentonii
(Daubenton’s bat), was measured with a novel quantitative
reverse transcription–polymerase chain reaction assay.
High levels of genomic RNA were found in the brain and
were also detectable in the tongue, bladder, and stomach.
B
at-mediated rabies has been reported in Europe for
more than 50 years. Two variants or genotypes are
now recognized that are distinct from rabies viruses of ter-
restrial mammals and new world bats (1). These are known
as European bat lyssaviruses (EBLVs). A third lyssavirus,
West Caucasian bat lyssavirus, has been isolated in eastern
Europe (2). EBLV type 1 (EBLV-1) is found throughout
mainland Europe and principally associated with the
Serotine bat (Eptesicus serotinus) (3). EBLV-2 is found in
Myotis  bats (Myotis daubentonii [Daubenton’s bat] and
Myotis dasycneme) and has been identified in 3 locations
in Europe: the Netherlands, the United Kingdom, and
Switzerland (Table 1). 
Two reports detail isolation of EBLV-2 from humans
who died of rabies encephalitis in Finland and the United
Kingdom (4,5). In addition, 4 isolations from Daubenton’s
bat have been reported in the United Kingdom since 1996.
Seroprevalence studies suggest that EBLV-2 is maintained
at certain sites in the United Kingdom at low levels (6).
However, the small number of bats infected with EBLV-2
and the nocturnal habits of insectivorous bats have ham-
pered attempts to understand the distribution, prevalence,
and transmission of the virus. Biting by Daubenton’s bats
was suspected in the 2 human cases from Finland and the
United Kingdom because both persons had handled this
species before symptoms developed. However, like rabies
virus, EBLV-2 does not persist in the environment outside
of an infected host, and alternative routes of infection
should be considered. Investigation of the second bat
detected viable EBLV-2 in the brain, and genomic RNA in
the heart, stomach, tongue, intestine, liver, and kidney by
using a sensitive nested reverse transcription–polymerase
chain reaction (RT-PCR) (7). This approach was unable to
quantify viral RNA within particular tissues. Since this
study, 2 additional cases have occurred in the United
Kingdom (Table 1). The investigation and quantification
of viral load within the infected host could provide evi-
dence for release of virus and methods of transmission.
The Study
In 2004, two EBLV-2 cases were identified in
Daubenton’s bats (Table 1). A diagnosis of EBLV-2 infec-
tion was confirmed on brain samples with a fluorescent-
antibody test, the mouse inoculation test, and a rapid
TaqMan assay (8). Attempts to culture EBLV-2 from
organs in both cases failed because of cytotoxicity of the
samples, which destroyed the cell monolayer. Sample dilu-
tion reduced the cytotoxic effects of the sample on the cell
monolayer (used for virus isolation) and enabled the devel-
opment of small foci of infection (bat 603/04). Heminested
RT-PCR detected virus RNA in brain, tongue, thyroid
gland, and bladder after the first round of amplification,
and in salivary gland, heart, lung, intestine, and stomach
after the second round of amplification. We suspect that
inappropriate storage of bat 696/04 in a freezer with
repeated freezing and thawing before submission resulted
in inactivation of virus in this sample. Heminested RT-
PCR detected virus RNA in samples of brain and stomach
after the first round of PCR, and in samples of tongue,
intestine, liver, and kidney after the second round of
amplification.
An EBLV-2-specific real-time PCR was developed to
measure virus genome to quantify the potential viral RNA
load within organs. Analysis was only attempted on those
organs with sufficient RNA within the sample (Figure).
Primers EBLVNa (5′-CCTGGCAGATGATGGGAC-3′)
and EBLVNb (5′-GCCTTTTATCTTGGATCACT-3′) are
located within the nucleoprotein gene and amplify a 221-
bp target. An amplified product from a previous case (5)
was purified by using the RNeasy kit (Qiagen, Valencia,
CA, USA) and quantified with a NanoDrop WD-1000
spectrophotometer (NanoDrop Technologies, Inc.,
Wilmington, DE, USA). This procedure enabled the
absolute number of copies of the amplicon to be calculat-
ed by its approximate molecular weight and Avogadro’s
number, as previously described (9). 
RNA was isolated from each organ with Trizol
(Invitrogen, Carlsbad, CA, USA) and quantified. Dilutions
were made to either 0.25 µg/µL (bat 603/04) or 1 µg/µL
(bat 696/04) to standardize the quantity of RNA used for
reverse transcription. Primer EBLVNa was used for cDNA
synthesis from the genomic (negative) sense strand as pre-
viously described (10). All PCRs were performed by using
SYBR Green JumpStart Taq ReadyMix (Sigma, Saint
Louis, MO, USA) and an MX3000P real-time thermal
DISPATCHES
1142 Emerging Infectious Diseases • www.cdc.gov/eid • Vol. 12, No. 7, July 2006
*Veterinary Laboratories Agency, Addlestone, Surrey, United
Kingdomcycler (Stratagene, La Jolla, CA, USA). Adilution series of
the control amplicon was amplified simultaneously with
the organ samples to create a standard curve for compari-
son of the threshold value (Ct) with target copy number
(Figure, panel A). 
Arepresentative plot of amplification curves from organ
samples taken from bat 696/04 is shown in the Figure, panel
B, with 10 µL of product separated by electrophoresis on a
1% agarose gel included for comparison. The quantitative
results for viral RNA load for both bats are shown in Table
2. In both cases, the brain had the highest viral genome load.
Virus RNA was consistently detected in the tongue, intes-
tine, and stomach. EBLV-2 was also found in the bladder of
bat 603/04 but not in the kidney of bat 696/04 from which
the bladder was not recovered because of carcass decompo-
sition. Virus was not detected in the liver of either bat.
Conclusions
The detection and quantification of EBLV-2 RNAin bat
organs by real-time PCR show the potential distribution of
this virus. The choice of organ tested in both cases was
severely limited by degradation of the carcass before
investigation. Furthermore, live virus could not be recov-
ered from many organs because of cytotoxicity of the sam-
ples and virus degradation caused by repeated freezing and
thawing. 
Viable virus was recovered from the brain of bat 603/04.
Since the brain is the main site of EBLV-2 replication, this
finding suggests that the virus displays a similar neurotro-
pism to classical rabies virus. Rabies virus, especially in the
late stages of disease, disseminates from the brain to other
innervated sites within the host (11). For EBLV-2, the
tongue was consistently found to contain detectable levels
of viral RNA in this study and a previous study (7).
Genomic RNAwas also found in the stomach and intestines
of 3 bats investigated (this study and [7]). All of these
organs are highly innervated tissues, although virus RNAin
the stomach could result from swallowing virus. 
Dissemination of rabies virus to the salivary glands and
subsequent virus shedding enables transmission through
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ed bats leads us to conclude that transmission of EBLV-2
may occur through biting. However, since EBLV-2
genome was detected in a bladder sample, we cannot
exclude the possibility of virus release from urine. In
future cases, where possible, organs such as the salivary
glands and lungs should be examined to provide further
evidence for the route of virus transmission between bats.
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Figure. Results of quantitative polymerase chain reaction (PCR) of
viral genome copies within organ samples taken from 2
Daubenton's bats infected with European bat lyssavirus type 2
(EBLV-2). A) Standard curve of duplicate dilutions of known quan-
tities of EBLV-2 amplicon. A 20% (vol/vol) sample (10-fold dilution
series) separated by electrophoresis on a 1% agarose gel is
shown in the inset. Ct, threshold value. B) Real-time PCR amplifi-
cation of EBLV-2 genomic RNA from organ samples from a bat
(696/04) in Lancashire, United Kingdom infected with EBLV-2. dR,
fluorescence change generated by a baseline-corrected algorithm
calculated from every amplification cycle. A 20% (vol/vol) sample
of each amplification separated by electrophoresis on a 1%
agarose gel is shown in the inset. Br, brain; To, tongue; Li, liver; Ki,
kidney; In, intestine; St, stomach; -, negative sample (no template);
+, positive sample from a previous human case (5).